Fourth Parallel Session
Track I – Policy sharing for KT
KTO Business Models
Most European universities established their KTOs 15-20 years ago and there is one thing we can say for sure: there is nothing like the successful business model for a KTO.
However, some KTOs are more successful than others: why?
This session shall highlight the concept of several different KTOs and discuss: the pros and cons of centralised units versus decentralised approaches; TTOs with regional responsibility versus working for only one institution; comprehensive offices versus specialised ones.
Three colleagues from very different TTOs will explain what, how and why they do what they do.
Benjamin Soffer, former Managing Director of T3, Israel
Location: Ballroom 2
Track II – Ownership
Intellectual Property, GDPR and Bioethics
Biotechnological inventions raise various ethical implications for national authorities, granting patent rights, and for universities and research institutions.
When it comes to clinical innovation, TT professionals are confronted with various issues such as management of clinical trials, informed consent, use of genetic data, and the new GPDR regulations.
This session will illustrate the topic with case studies, and share experiences on how to deal with ethical issues in technology transfer.
Christian Stein, CEO, Ascenion GmbH, Germany
Location: Ballroom 3
Track III – Skills for KTO
University Venture Funds
In 2016 Trinity College Dublin and University College Dublin launched a Venture Fund together with the European Investment Fund, Atlantic Bridge, Enterprise Ireland and other partners. The €60m fund is aimed at early stage research-based companies with global potential.
In this session, Trinity College Dublin will unpack how to go about establishing a university venture the fund, the technical details and the aims and early results.
Tom Hockaday, Technology Transfer Innovation, UK
Declan Weldon, Head of Research Commercialisation, Trinity College Dublin, Ireland
Location: Elm & Oak